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Abstract
Objective: To develop, test, and validate the performance of ICD-10-CM claims-
based case definitions for identifying children with sickle cell anemia (SCA).
Data Sources: Medicaid administrative claims (2016) for children <18 years with po-
tential SCA (any D57x diagnosis code) and newborn screening records from Michigan 
and New York State.
Study Design: This study is a secondary data analysis.
Data Collection/Extraction Methods: Using specific SCA-related (D5700, D5701, 
and D5702) and nonspecific (D571) diagnosis codes, 23 SCA case definitions were 
applied to Michigan Medicaid claims (2016) to identify children with SCA. Measures 
of performance (sensitivity, specificity, area under the ROC curve) were calculated 
using newborn screening results as the gold standard. A parallel analysis was con-
ducted using New York State Medicaid claims and newborn screening data.
Principal Findings: In Michigan Medicaid, 1597 children had ≥1 D57x claim; 280 (18 
percent) were diagnosed with SCA. Measures of performance varied, with sensitivi-
ties from 0.02 to 0.97 and specificities from 0.88 to 1.0. The case definition of ≥1 
outpatient visit with a SCA-related or D571 code had the highest area under the 
ROC curve, with a sensitivity of 95 percent and specificity of 92 percent. The same 
definition also had the highest performance in New York Medicaid (n = 2454), with a 
sensitivity of 94 percent and specificity of 86 percent.
Conclusions: Children with SCA can be accurately identified in administrative claims 
using this straightforward case definition. This methodology can be used to monitor 
trends and use of health services after transition to ICD-10-CM.
K E Y W O R D S
administrative claims, ICD-10-CM, sickle cell anemia
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1  | INTRODUC TION
Sickle cell disease is an inherited blood disorder that affects 
approximately 100 000 Americans.1 There are many sub-
types of sickle cell disease. Sickle cell anemia (SCA) is a col-
lective term which includes subtypes hemoglobin (Hb) SS and 
Hbβ0thalassemia.2 Children with SCA are at risk for numerous 
morbidities, such as pain, serious infections, and stroke.3 At least 
half will experience at least one hospitalization related to pain 
within a year.4 Children with SCA are at 100 times the risk of in-
fection and 300 times the risk of stroke as compared to a child 
without SCA.5,6
The National Heart, Lung, and Blood Institute (NHLBI) de-
veloped evidence-based guidelines for preventive care among 
those living with sickle cell disease; many of these recommen-
dations are targeted toward those with SCA.2 For example, the 
NHLBI recommends that children with SCA receive the medica-
tion hydroxyurea to prevent pain crises, antibiotic prophylaxes to 
prevent infection, and transcranial Doppler (TCD) screening to 
identify children at the highest risk of stroke.2 As a result of the 
comorbidities, complications, and receipt of preventive care, chil-
dren with SCA experience numerous routine and acute encoun-
ters with the health care system.7-19 These encounters result in 
significant monetary and social costs for families and the health 
care system.19
The importance of the receipt of preventive care coupled with 
high health care utilization and cost emphasizes the need for popu-
lation-based assessments of the quality of care among children with 
SCA. Such assessments may be particularly challenging as SCA is 
a rare disease in the US. Given relatively frequent health services 
utilization among children with SCA, administrative billing claims, 
which are widely available for publically and commercially insured 
populations, may provide a useful data source for tracking popula-
tion-based health and quality of care.20
Diagnosis codes, which are contained in administrative claims 
databases, are commonly used to identify children with chronic 
diseases such as asthma, diabetes, and inflammatory bowel dis-
ease.21-24 Several studies have demonstrated that administrative 
claims using ICD-9-CM diagnosis codes can be used to accurately 
identify children with sickle cell disease.7,25,26 However, these defi-
nitions are subject to two limitations in assessing health services 
among children with SCA: (a) identification of children with sickle 
cell disease more broadly as opposed to children with SCA; and (b) 
use of ICD-9-CM diagnosis codes. Beginning in October 1, 2015, 
the Centers for Medicare and Medicaid Services (CMS) required 
the use of ICD-10-CM diagnosis codes in the United States.27 
Therefore, any definitions using ICD-9-CM diagnosis codes are no 
longer feasible for any assessments of administrative claims data 
after September 2015. To address these limitations, we developed, 
tested, and validated the performance of ICD-10-CM case defini-
tions for identifying children with SCA. The goal of this analysis is 
to support evaluation of health services and receipt of preventive 
care among these children.
2  | METHODS
We developed, tested, and validated the performance of ICD-10-CM 
case definitions for SCA through the following 4-step process: (a) de-
veloping candidate SCA case definitions; (b) identifying a test popu-
lation for the definitions; (c) testing the accuracy of candidate case 
definitions; and (d) testing case definitions within an independent 
population.
2.1 | Developing candidate SCA case definitions
The requisite transition from ICD-9-CM to ICD-10-CM diagnosis 
codes in the United States has revealed several potential difficulties 
related to case definitions using administrative claims.27 The transi-
tion introduced a coding nuance that is potentially quite impactful 
when evaluating health services related to SCA. The relevant ICD-
10-CM diagnosis codes include three billable categories related to 
acute care for SCA: D5700 (HbSS with crisis); D5701 (HbSS with 
acute chest syndrome); and D5702 (HbSS with splenic sequestra-
tion). The ICD-10 diagnosis code D570 is nonbillable per CMS.28 
There are no specific ICD-10 diagnosis codes that characterize care 
related to sickle cell anemia without a crisis. While there is an ICD-
10-CM code (D571), this code is for sickle cell disease without crisis, 
but does not stipulate a specific subtype of sickle cell disease. Use 
of this general diagnosis code has unknown implications for accu-
rate case identification of children with SCA; consequently, we de-
veloped and tested several case definitions that included the D571 
diagnosis code.
We developed three mutually exclusive claims categories of 
health services related to SCA: outpatient visits, emergency de-
partment (ED) visits, and inpatient hospitalizations. Each category 
was defined using code sets to identify health service encounters 
from validated HEDIS® definitions based on Current Procedural 
Terminology (CPT) procedure codes, Uniform Billing Revenue codes, 
What this study adds
• Accurate identification of children with sickle cell ane-
mia using administrative claims is essential for track-
ing health services, receipt of preventive care, and 
outcomes.
• We developed, tested, and validated the performance 
of ICD-10-CM case definitions for identifying children 
with sickle cell anemia against newborn screening re-
cords in two large state Medicaid programs.
• The case definition of ≥1 outpatient visit with a sickle 
cell anemia–related or D571 code accurately identified 
children with sickle cell anemia.
• This methodology can be used to monitor trends and 
use of health services after transition to ICD-10-CM.
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and ICD-10-CM diagnosis codes.29 The HEDIS® definition for out-
patient visits does not include visits for laboratory only. We also 
developed a case definition comprised of the overall count of SCA 
claims, irrespective of service type. The combinations of service cat-
egories within our ICD-10-CM case definitions were informed by our 
previous work validating ICD-9-CM case definitions.7
The health service categories were then used to develop 23 can-
didate case definitions, varying from a simple count of claims to var-
ious combinations of outpatient visits and/or inpatient admissions. 
Definitions with simple counts of claims included any health service 
claim with a diagnosis code, irrespective of service or location (eg, in-
patient, outpatient, emergency department). Specific types of health 
services were considered, as these services can have different pre-
dictive values for identifying cases in other chronic conditions.30,31 
Counts of claims or service types ranged from at least one to at least 
3; previous findings indicate that little specificity would be gained 
by requiring additional claims and would result in loss of sensitiv-
ity.7 Definitions with varying lengths between outpatient visits were 
also considered, consistent with other administrative claims-based 
definitions for chronic conditions.32 It is important to note that defi-
nitions also varied by which ICD-10-CM codes were considered a 
SCA-related event; 14 case definitions only included D5700, D5701, 
and D5702 diagnosis codes while the remaining nine definitions also 
included the nonspecific D571 diagnosis code. Table 1 summarizes 
each candidate SCA case definition and the diagnosis codes upon 
which each is based. Case definitions are uniquely identified with 
letters (A-W) for subsequent reference.
2.2 | Identifying a test population
Our test population included children in Michigan Medicaid aged 1 
through 17 years who potentially had SCA, classified as those having 
at least 1 claim with a D57x diagnosis within the 2016 study period. 
Children were continuously enrolled for the entire calendar year, 
and we excluded those with any other form of health insurance to 
maximize the completeness of health service claims within the study 
period.
Children meeting eligibility criteria were linked to Michigan birth 
certificates using child’s name, birthdate, and sex; unlinked records 
were manually reviewed. Birth certificates were linked to NBS records 
using a previously validated method.33 Children were classified as 
having: (a) confirmed SCA (HbSS, Hbβ0thalassemia); (b) not SCA; or (c) 
unknown status. An unknown NBS record status could result from situ-
ations whereby the child’s Medicaid record cannot be linked to an elec-
tronic birth certificate (eg, name change and born in another state), or 
as a consequence of an unconfirmed NBS result. In Michigan, any child 
with an abnormal hemoglobin result suggestive of disease on a NBS 
is referred to a hematologist for confirmatory testing; these results 
are reported back to the NBS Program. Therefore, a child classified as 
having SCA in their Michigan NBS record has received confirmatory 
testing in addition to normal screening procedures. Michigan children 
with other subtypes of sickle cell disease, such as HbSC or HbSD, or 
normal hemoglobin, were classified as not SCA; those with unknown or 
undocumented NBS results were excluded from further analysis. For 
children in our testing population, descriptive statistics of age and sex 
were calculated both overall and by status (SCA/not SCA).
2.3 | Testing the accuracy of candidate case 
definitions
Measures of performance were calculated for all 23 candidate case 
definitions among children in our test population with either con-
firmed SCA or not SCA, as determined through Michigan NBS testing 
TA B L E  1   Candidate case definitions developed for identification 
of children with sickle cell anemia (SCA)
Definition Description




SCA-related emergency department (ED) visits (D5700, D5701, and 
D5702)
D ≥1 ED visit
E ≥2 ED visits
F ≥3 ED visits




SCA-related outpatient visits (D5700, D5701, and D5702)
J ≥1 outpatient visit
K ≥2 outpatient visits ≥30 d apart
L ≥3 outpatient visits, each ≥30 d apart
M ≥2 outpatient visits, ≥7 d apart
N ≥3 outpatient visits, each ≥7 d apart
SCA-related outpatient visits, including nonspecific sickle cell code 
(D5700, D5701, D5702, and D571)
O ≥1 outpatient visit
P ≥2 outpatient visits, ≥30 d apart
Q ≥3 outpatient visits, each ≥30 d apart
R ≥2 outpatient visits, ≥7 d apart
S ≥3 outpatient visits, each ≥7 d apart
Counts of SCA claims, including nonspecific sickle cell code (D5700, 





W ≥2 SCA or D571 outpatient visits, each ≥7 d 
apart OR ≥ 1 SCA-related hospitalization
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and follow-up. Confirmed Michigan NBS results were used as our 
gold standard for measures of performance calculations. Measures 
of case definition performance included sensitivity, specificity, and 
area under the receiver operating characteristic (ROC) curve.34
2.4 | Testing case definitions within an 
independent population
Similar to the approach used in Michigan, we conducted a parallel 
analysis using the identical 23 candidate case definitions tested in 
Michigan in conjunction with claims and NBS data obtained from 
the New York State (NYS) Medicaid program. Children born in NYS 
in years 2006-2013 with sickle cell disease, as identified by NBS and 
confirmatory testing, were matched to corresponding Medicaid re-
cords as previously described.35 The NYS population consisted of 
children aged 3-10 years who had at least 1 Medicaid claim with 
a D57x diagnosis during the 2016 study period; complete NYS 
NBS data were not available for children younger than 3 or older 
than 10 years of age. Children were continuously enrolled in NYS 
Medicaid for the entire calendar year with no other forms of health 
insurance within the study period.
Children were classified as having either confirmed SCA (HbSS, 
Hbβ0thalassemia) or not SCA. In NYS, any child with an abnormal 
hemoglobin result on an NBS is referred to a hematologist for con-
firmatory testing; these results are reported back to the NYS NBS 
Program. Therefore, a child classified as having SCA within NBS 
records has been subject to the normal NBS procedures, as well 
as additional confirmatory testing. NYS data coding limitations re-
quired that children with other subtypes of sickle cell disease, nor-
mal hemoglobin, and unknown NBS results be classified as not SCA. 
For each candidate case definition, measures of performance were 
calculated using NYS confirmed NBS results as the gold standard. 
Measures of performance included sensitivity, specificity, and area 
under the ROC curve.
Sensitivity Analyses: We performed two sensitivity analyses 
to assess the impact of additional codes and age upon our results. 
First, although the three-digit code D570 is not billable per CMS 
guidance, we assessed occurrence of this code among children in 
the Michigan Medicaid study population.28 Second, we assessed 
the sensitivity and specificities of our most accurate definition 
by stratifying the children into the following age-groups within 
the Michigan Medicaid population: 1-5 years, 6-11 years, and 
12-17 years. We also assessed the sensitivity and specificity of 
the same case definition when the Michigan Medicaid study pop-
ulation was limited to age 3-10 for a direct comparison to the NY 
Medicaid population.
3  | RESULTS
In Michigan, 1597 children 1 through 17 years old had ≥1 D57x claim 
and were continuously enrolled in Michigan Medicaid in 2016 with 
no other forms of health insurance. Among these children, 280 (18 
percent) were diagnosed with SCA and 1177 (74 percent) were not 
SCA; 140 (8 percent) were excluded due to an unknown NBS result. 
Among the 1457 children in the population with known NBS results, 
average age as of January 1, 2016, was 7.2 (SD = 4.7) years, 49 per-
cent were female, and 85 percent were recorded as non-Hispanic 
black within Medicaid records (Table 2).
Measures of performance varied substantially across the 23 
candidate case definitions tested in Michigan, with sensitivities 
ranging widely (0.03-0.97) and specificities varying from 0.81 to 
1.0 (Table 3). As expected, as definitions moved from less to more 
 
Michigan Medicaid New York State Medicaid
Sickle cell anemia 
(SCA) (n = 280)
Not SCA 




Male 137 (49%) 611 (52%) 259 (51%) 1023 (52%)
Female 143 (51%) 566 (48%) 246 (49%) 926 (48%)
Race
Non-Hispanic black 242 (86%) 1002 (85%) 328 (65%) 1114 (57%)
Non-Hispanic white 7 (3%) 74(6%) 8 (2%) 53 (3%)
Hispanic <5 35 (3%) 78 (15%) 312 (16%)
Unknown race/
ethnicity
28 (10%) 59 (5%) 46 (9%) 353 (18%)
Asian/Pacific Islander <5 <5 <5 13 (1%)
Other N/A N/A 44 (8%) 100 (5%)
American Indian/
Alaskan Native
<5 <5 <5 <5
Age (years), mean 
(standard deviation)
8.7 (4.6) 6.8 (4.7) 6.5 (2.3) 6.0 (2.3)
TA B L E  2   Demographic characteristics 
of children with at least 1 D57x claim in 
2016
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restrictive (ie, one outpatient visit to two outpatient visits related to 
SCA), sensitivities decreased and specificities increased. Each defi-
nition that included a D571 diagnosis code in addition to the SCA di-
agnosis codes (D5700, D5701, and D5702) had a substantially higher 
sensitivity; decreases in specificity were small when comparing defi-
nitions with and without the nonspecific D571 diagnosis code. Area 
under the ROC curve ranged from 0.51 to 0.93. The case definition 
of ≥1 outpatient visit with a SCA-related or D571 code had the high-
est area under the ROC curve (0.93), with a sensitivity of 94 percent 
and specificity of 92 percent.
In NYS, there were 2454 children that were 3-10 years old, had 
≥1 D57x claim, and were continuously enrolled in NYS Medicaid in 
2016 with no other forms of health insurance. Among these children, 
505 (21 percent) were diagnosed with SCA, and 1949 (79 percent) 
were either not SCA or did not have an NBS result. Among the 2454 
children in the NYS Medicaid population, average age as of January 
1, 2016, was 6.1 (SD = 2.31) years, 48 percent were female, and 59 
percent were recorded as non-Hispanic black (Table 2).
Among the 23 candidate case definitions validated in NYS, sen-
sitivities ranged widely from 0.01 to 0.98, and specificities ranged 
from 0.81 to 1.0 (Table 3). Similar to Michigan, we found that defi-
nitions including a D571 diagnosis code had a higher sensitivity as 
compared to those with only the SCA diagnosis codes, with small 
decreases in specificity. Area under the ROC curve ranged from 
0.51 to 0.90. The same case definition of ≥1 outpatient visit with 
a SCA-related or D571 code had the highest area under the ROC 
curve (0.90), with a sensitivity of 94 percent and specificity of 86 
percent.
Sensitivity analyses: Consistent with CMS billing guidance, the 
nonbillable ICD-10 code D570 was not found in any claim among our 
Michigan Medicaid study population. When the most accurate case 
definition (definition O) was applied to stratified age-groups, there 
were no clinically relevant changes in the sensitivities and specifici-
ties of the definition as compared to NBS records (Table 4).
4  | DISCUSSION
We conducted this study to develop, test, and validate a case defi-
nition for identifying children with SCA using administrative claims 
data from two large state Medicaid programs. To our knowledge, 
this is the first US study to test the accuracy of using ICD-10-CM 
diagnosis codes to identify children with SCA. We found that our 
best performing case definition, one outpatient visit with a SCA 
(D5700, D5701, and D5702) or D571 ICD-10-CM diagnosis code, 
had high sensitivity and specificity in both our populations. Given 
the high accuracy of our case definition, our findings lend confi-
dence that this definition will enable accurate, population-based 
assessments of the quality of care and health services among chil-
dren with SCA when using administrative claims. Importantly, our 
results demonstrate that a high degree of accuracy in identifying 
children with SCA can be achieved in settings where NBS results 
are not available.
There are numerous case definitions developed to identify chil-
dren with sickle cell disease using ICD-9-CM diagnosis codes that 
cannot be applied to claims data reporting ICD-10-CM diagnosis 
codes.7 These ICD-9-CM definitions vary from a simple count of 
sickle cell disease–related diagnosis codes to combinations of out-
patient and inpatient visits.36-41 The majority of these ICD-9-CM 
definitions were developed to identify children with any form of 
sickle cell disease, as opposed to children with a specific diagno-
sis of SCA. The most accurate ICD-10-CM definition to specif-
ically identify children with SCA is straightforward and easy to 
implement. It has been tested against the genetic gold standard of 
NBS records. The use of NBS records ensures the candidate case 
definitions are tested against a gold standard that has nearly zero 
misclassification of hemoglobin status. This gold standard is more 
accurate than those used in many other claims-based validation 
work, which often use medical records or registry data to confirm 
case status.42-44 As health service researchers continue to iden-
tify opportunities for improvement in the care of these high-risk 
children using administrative claims, it would be advantageous to 
begin use of this validated and accurate case definition. Further, 
results obtained across studies using the same case definition may 
be more comparable than studies using a definition with unknown 
sensitivity and specificity.
Our study shows that including a D571 diagnosis code (sickle 
cell disease without crisis) was essential for identifying children 
with SCA, as results showed significantly improved sensitivity, 
with a small negative impact on specificity. This was a particularly 
surprising finding given the lack of specificity for the SCA subtype 
of this diagnosis code. For example, definitions O and J both re-
quire one outpatient visit related to SCA; however, definition O 
also allows for the outpatient visit to be coded with the nonspe-
cific D571 code. Definition J had a sensitivity of 16 percent; defi-
nition O had a sensitivity of 94 percent. Specificities for the two 
definitions were 99 percent (definition J) and 92 percent (defini-
tion O). The surprisingly high specificity for the nonspecific D571 
code presumably reflects the availability of specific ICD-10-CM 
codes for other subtypes of sickle cell disease without crisis, such 
as D57.20 (HbSC without crisis). It is also worthwhile to note that 
our specificity was calculated among the population of children 
with a claim reporting a D57x code. This would tend to under-
state the specificity, compared to the entire Medicaid population. 
Among the entire Medicaid population, the specificity would be 
over 99 percent due to the substantially increased number of true 
negatives.
This study has limitations; candidate case definitions were tested 
and validated in two state Medicaid programs. Michigan and NYS 
Medicaid programs may not be reflective of all of the nuances that 
exist between different state administrative claims databases, yet 
our study is strengthened by the consistency of results across two 
large, diverse Medicaid populations. Our results were also limited to 
children enrolled in Medicaid in a small timeframe; however, previ-
ous studies indicate that nearly 90 percent of children with SCA are 
enrolled in Medicaid at some point in time.45 Our study is only able 
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to identify children with SCA that utilize health care. Any child with 
SCA that does not have SCA-related health care needs would not 
be captured within this case definition, although we do expect this 
proportion of children to be small and would affect all case defini-
tions equally. For example, we anticipate that less than 10 children 
with SCA would be without a D57x diagnosis code within a year; 
even when accounting for these children, the sensitivity of our case 
definition would continue to be over 90 percent in the Michigan 
Medicaid population. Finally, we did not test how this case definition 
would perform among children outside of our study population age 
TA B L E  3   Measures of performance for candidate case definitions
Definition Description
Michigan Medicaid New York State Medicaid
Sensitivity Specificity
Area under the 
ROC curve Sensitivity Specificity
Area under 
the ROC curve
Counts of sickle cell anemia (SCA) claims (D5700, D5701, and D5702)
A ≥1 claim 0.56 0.94 0.75 0.52 0.92 0.72
B ≥2 claims 0.48 0.96 0.72 0.33 0.97 0.65
C ≥3 claims 0.39 0.97 0.68 0.22 0.99 0.60
SCA-related emergency department (ED) visits (D5700, D5701, and D5702)
D ≥1 ED visit 0.45 0.95 0.70 0.22 0.96 0.59
E ≥2 ED visits 0.34 0.97 0.65 0.07 0.99 0.53
F ≥3 ED visits 0.20 0.98 0.59 0.03 1.00 0.51
SCA-related inpatient hospitalizations (D5700, D5701, and D5702)
G ≥1 hospitalization 0.33 0.99 0.66 0.34 0.98 0.66
H ≥2 hospitalizations 0.30 0.99 0.65 0.13 1.00 0.57
I ≥3 hospitalizations 0.25 0.99 0.62 0.07 1.00 0.53
SCA-related outpatient visits (D5700, D5701, and D5702)
J ≥1 outpatient visit 0.16 0.99 0.58 0.30 0.96 0.63
K ≥2 outpatient visits 
≥30 d apart
0.05 1.00 0.53 0.04 1.00 0.52
L ≥3 outpatient visits, 
each ≥30 d apart
0.03 1.00 0.51 0.01 1.00 0.51
M ≥2 outpatient visits, 
≥7 d apart
0.06 1.00 0.53 0.06 1.00 0.53
N ≥3 outpatient visits, 
each ≥7 d apart
0.03 1.00 0.51 0.03 1.00 0.51
SCA-related outpatient visits, including nonspecific sickle cell code (D5700, D5701, D5702, and D571)
O ≥1 outpatient visit 0.94 0.92 0.93 0.94 0.86 0.90
P ≥2 outpatient visits, 
≥30 d apart
0.85 0.97 0.91 0.62 0.96 0.79
Q ≥3 outpatient visits, 
each ≥30 d apart
0.70 0.99 0.85 0.45 0.98 0.71
R ≥2 outpatient visits, 
≥7 d apart
0.86 0.97 0.91 0.70 0.95 0.82
S ≥3 outpatient visits, 
each ≥7 d apart
0.73 0.99 0.86 0.59 0.96 0.78
Counts of SCA claims, including nonspecific sickle cell code (D5700, D5701, D5702, and D571)
T ≥1 claim 0.97 0.81 0.89 0.98 0.81 0.89
U ≥2 claims 0.94 0.91 0.92 0.89 0.89 0.89
V ≥3 claims 0.91 0.93 0.92 0.78 0.92 0.85
Combination
W ≥2 SCA or D571 
outpatient visits, each 
≥7 d apart OR ≥ 1 SCA-
related hospitalization
0.87 0.96 0.92 0.75 0.94 0.84
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range. Specifically, we did not assess case definitions for identifying 
infants (ie, <1 year of age) with SCA, or for individuals 18 years of 
age and older.
In conclusion, children with SCA can be accurately identified 
using this straightforward case definition. This methodology can be 
used to monitor trends and use of health services after transition to 
ICD-10-CM. Further studies should apply this definition to publically 
and commercially insured populations for prospective and contin-
uous monitoring of opportunities to improve care among children 
with SCA, a vulnerable group of children at high risk for significant 
morbidity across the lifespan.
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